B

Brainstorm Cell Therapeutics
D

BCLI

2.13000
USD
-0.17
(-7.39%)
Market Closed
Volume
1,379
EPS
-2
Div Yield
-
P/E
-1
Market Cap
12,148,297
Related Instruments
    A
    APLS
    0.290
    (0.96%)
    30.390 USD
    A
    ASND
    -4.910
    (-3.75%)
    126.150 USD
    A
    ATHA
    0.00810
    (1.52%)
    0.54010 USD
    M
    MBIO
    -0.14000
    (-3.29%)
    4.12000 USD
    M
    MDB
    2.86
    (1.11%)
    260.72 USD
    Q
    QURE
    0.390
    (2.61%)
    15.310 USD
    R
    RYTM
    -0.210
    (-0.37%)
    57.270 USD
    V
    VYGR
    0.22000
    (4.21%)
    5.45000 USD
    More
News

Title: Brainstorm Cell Therapeutics

Sector: Healthcare
Industry: Biotechnology
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.